Independent association between prostate-specific antigen nadir and PSA progression-free survival in first-line abiraterone acetate treatment in castration-resistant prostate cancer patients: a pilot study

• Published in: Frontiers in oncology Vol. 14; p. 1348324
• Main Authors: Du, Hong, Xie, Wenjuan, Chen, Wenqiang, Wang, Yu, Liao, Yong, Qiu, Mingxing, Li, Jun
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.06.2024
• Subjects: association; generalized additive model; Oncology; progression free survival; prostate-specific antigen (PSA) decline and kinetics; subgroup analysis; association; subgroup analysis; prostate-specific antigen (PSA) decline and kinetics; progression free survival; generalized additive model
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2024.1348324

There is limited evidence regarding the correlation between prostate-specific antigen (PSA) kinetics and clinical outcomes. Therefore, after regulating other covariates, we studied patients with castration-resistant prostate cancer who received abiraterone acetate as the first-line treatment. In this study, we investigated whether time to PSA nadir was independently associated with PSA progression-free survival (PFS). As a retrospective cohort study, this study contained a total of 77 castration-resistant prostate cancer patients who received abiraterone acetate from October 2015 to April 2021 in a Chinese hospital. The dependent variable was PSA-PFS. The objective independent variable was time to PSA nadir (TTPN). Covariates involved in this study included age, duration of androgen deprivation therapy (ADT), PSA level at baseline, time of 50% PSA decline, time of PSA decline to nadir, Gleason score, bone metastasis, previous treatment, PSA decline <50% in 3 months, PSA to nadir in 3 months, PSA decline <90%, PSA decline <0.2 ng/mL, and PSA flare. For the 77 subjects, their mean age was 72.70 ± 8.08 years. Fully calibrated linear regression findings indicated that PSA decline and kinetics were positively associated with PFS (months) after adjusting confounders (β = 0.77, 95% CI: 0.11-1.44). A non-linear relationship was not detected between PSA decline or PSA kinetics and progression-free survival. According to the data of this study, there was a correlation between early PSA changes and patients treated with abiraterone acetate.